About Cumberland Pharmaceuticals (NASDAQ:CPIX)
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on acquiring, developing, and commercializing branded prescription products for hospital acute care and gastroenterology markets in the United States and internationally. It marketed products include Acetadote (acetylcysteine) injection for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) injection for the treatment of pain and fever; Kristalose (lactulose) for oral solution, a prescription laxative; Vaprisol (conivaptan) injection for treating hyponatremia; Omeclamox-Pak for the treatment of H. pylori infection and duodenal ulcer disease; and Ethyol (amifostine) for injection to treat oncology patients. The company's product candidates in Phase II clinical trials comprise Hepatoren (ifetroban) injection for the treatment of hepatorenal syndrome; Boxaban (ifetroban) oral capsule for the treatment of aspirin-exacerbated respiratory disease; Vasculan (ifetroban) oral capsule for the treatment of systemic sclerosis; and Portaban for the treatment of portal hypertension. Its pre-approval products consist of Methotrexate injection for treating active rheumatoid, juvenile idiopathic, and psoriatic arthritis, as well as disabling psoriasis; and Totect injection for emergency oncology intervention, which helps to reverse the toxic effects of anthracycline chemotherapy in case of extravasation. The company markets and sells its products through sales representatives and district managers. Cumberland Pharmaceuticals Inc. has a strategic alliance with Clinigen Group plc, Nordic Group B.V., and Cumberland Emerging Technologies. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:CPIX
CUSIP23077010
Phone615-255-0068
Debt
Debt-to-Equity Ratio0.15%
Current Ratio3.88%
Quick Ratio3.50%
Price-To-Earnings
Trailing P/E Ratio-93.00
Forward P/E Ratio-29.13
P/E GrowthN/A
Sales & Book Value
Annual Sales$41.15 million
Price / Sales2.55
Cash Flow$0.1078 per share
Price / Cash62.13
Book Value$4.06 per share
Price / Book1.65
Profitability
EPS (Most Recent Fiscal Year)($0.07)
Net Income$-7,970,000.00
Net Margins-19.39%
Return on Equity-1.55%
Return on Assets-1.14%
Miscellaneous
Employees84
Outstanding Shares15,650,000
Cumberland Pharmaceuticals (NASDAQ:CPIX) Frequently Asked Questions
What is Cumberland Pharmaceuticals' stock symbol?
Cumberland Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPIX."
How were Cumberland Pharmaceuticals' earnings last quarter?
Cumberland Pharmaceuticals (NASDAQ:CPIX) posted its earnings results on Tuesday, March, 6th. The specialty pharmaceutical company reported $0.01 earnings per share for the quarter. The specialty pharmaceutical company had revenue of $11.65 million for the quarter. Cumberland Pharmaceuticals had a negative net margin of 19.39% and a negative return on equity of 1.55%. View Cumberland Pharmaceuticals' Earnings History.
When is Cumberland Pharmaceuticals' next earnings date?
What price target have analysts set for CPIX?
1 analysts have issued 12-month price targets for Cumberland Pharmaceuticals' stock. Their forecasts range from $9.25 to $9.25. On average, they expect Cumberland Pharmaceuticals' stock price to reach $9.25 in the next twelve months. View Analyst Ratings for Cumberland Pharmaceuticals.
Who are some of Cumberland Pharmaceuticals' key competitors?
Some companies that are related to Cumberland Pharmaceuticals include Menlo Therapeutics (MNLO), Ra Pharmaceuticals (RARX), POXEL (PXXLF), Xoma (XOMA), Marinus Pharmaceuticals (MRNS), Summit Therapeutics (SMMT), Nabriva Therapeutics (NBRV), Scpharmaceuticals (SCPH), Teligent (TLGT), Protagonist Therapeutics (PTGX), Zafgen (ZFGN), Evolus (EOLS), Spero Therapeutics (SPRO), Spring Bank Pharmaceuticals (SBPH), Avid Bioservices (CDMO), Kamada (KMDA), Proteostasis Therapeutics (PTI) and Intec Pharma (NTEC).
Who are Cumberland Pharmaceuticals' key executives?
Cumberland Pharmaceuticals' management team includes the folowing people:
- Mr. A. J. Kazimi MBA, Founder, Chairman, Chief Exec. Officer and Pres (Age 60)
- Mr. Michael P. Bonner, Chief Financial Officer and Sr. Director of Fin. & Accounting (Age 41)
- Mr. Leo B. Pavliv R.Ph., Chief Devel. Officer and Exec. VP of Operations (Age 57)
- Mr. James Lowrance Herman, Chief Compliance Officer and Sr. VP of National Accounts (Age 63)
- Mr. Martin E. Cearnal, Chief Commercial Officer, Exec. VP and Director (Age 73)
Has Cumberland Pharmaceuticals been receiving favorable news coverage?
News articles about CPIX stock have trended somewhat positive recently, according to Accern Sentiment. The research group rates the sentiment of press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Cumberland Pharmaceuticals earned a media sentiment score of 0.16 on Accern's scale. They also gave media stories about the specialty pharmaceutical company an impact score of 44.54 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
How do I buy shares of Cumberland Pharmaceuticals?
Shares of CPIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cumberland Pharmaceuticals' stock price today?
One share of CPIX stock can currently be purchased for approximately $6.70.
How big of a company is Cumberland Pharmaceuticals?
Cumberland Pharmaceuticals has a market capitalization of $101.90 million and generates $41.15 million in revenue each year. The specialty pharmaceutical company earns $-7,970,000.00 in net income (profit) each year or ($0.07) on an earnings per share basis. Cumberland Pharmaceuticals employs 84 workers across the globe.
How can I contact Cumberland Pharmaceuticals?
Cumberland Pharmaceuticals' mailing address is 2525 WEST END AVENUE SUITE 950, NASHVILLE TN, 37203. The specialty pharmaceutical company can be reached via phone at 615-255-0068 or via email at [email protected]
MarketBeat Community Rating for Cumberland Pharmaceuticals (CPIX)
MarketBeat's community ratings are surveys of what our community members think about Cumberland Pharmaceuticals and other stocks. Vote "Outperform" if you believe CPIX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CPIX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Cumberland Pharmaceuticals (NASDAQ:CPIX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
1 Wall Street analysts have issued ratings and price targets for Cumberland Pharmaceuticals in the last 12 months. Their average twelve-month price target is $9.25, suggesting that the stock has a possible upside of 38.06%. The high price target for CPIX is $9.25 and the low price target for CPIX is $9.25. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | N/A | N/A | N/A |
| Consensus Rating Score: | 3.00 | N/A | N/A | N/A |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $9.25 | N/A | N/A | N/A |
| Price Target Upside: | 38.06% upside | N/A | N/A | N/A |
Cumberland Pharmaceuticals (NASDAQ:CPIX) Consensus Price Target History
Cumberland Pharmaceuticals (NASDAQ:CPIX) Analyst Ratings History
Show:
| Date | Brokerage | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 4/17/2018 | B. Riley | Initiated Coverage | Buy | $9.25 | High |  |
(Data available from 4/23/2016 forward)
Cumberland Pharmaceuticals (NASDAQ:CPIX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Cumberland Pharmaceuticals (NASDAQ CPIX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 39.50%
Institutional Ownership Percentage: 34.58%
Cumberland Pharmaceuticals (NASDAQ CPIX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/19/2018 | Michael Bonner | CFO | Buy | 300 | $6.72 | $2,016.00 | 15,997 | |
| 11/22/2017 | Michael Bonner | CFO | Buy | 250 | $7.81 | $1,952.50 | 15,697 | |
| 11/20/2017 | Kenneth Krogulski | Director | Buy | 3,300 | $7.55 | $24,915.00 | 154,300 | |
| 8/23/2017 | Michael Bonner | CFO | Buy | 500 | $6.72 | $3,360.00 | 15,447 | |
| 5/31/2017 | Michael Bonner | CFO | Buy | 300 | $6.95 | $2,085.00 | 14,947 | |
| 4/7/2017 | Thomas R. Lawrence | Director | Sell | 6,000 | $6.40 | $38,400.00 | | |
| 3/23/2017 | Michael Bonner | CFO | Buy | 900 | $6.42 | $5,778.00 | 12,800 | |
| 11/17/2016 | Michael Bonner | CFO | Buy | 900 | $5.50 | $4,950.00 | 11,900 | |
| 8/17/2016 | Thomas R Lawrence | Director | Sell | 3,000 | $4.60 | $13,800.00 | 45,381 | |
| 5/26/2016 | Thomas R Lawrence | Director | Sell | 3,000 | $4.55 | $13,650.00 | 48,381 | |
| 11/19/2015 | Thomas R Lawrence | Director | Sell | 4,000 | $5.61 | $22,440.00 | 50,381 | |
| 3/19/2015 | Thomas R Lawrence | Director | Sell | 6,000 | $6.95 | $41,700.00 | | |
| 11/20/2014 | Thomas R Lawrence | Director | Sell | 10,000 | $5.12 | $51,200.00 | | |
| 8/21/2014 | Thomas R Lawrence | Director | Sell | 15,000 | $5.08 | $76,200.00 | | |
| 3/19/2014 | Thomas Lawrence | Director | Sell | 20,000 | $4.54 | $90,800.00 | 80,381 | |
(Data available from 1/1/2013 forward)
Cumberland Pharmaceuticals (NASDAQ CPIX) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Cumberland Pharmaceuticals Forecasted to Post Q1 2018 Earnings of ($0.02) Per Share (CPIX)
www.americanbankingnews.com - April 19 at 7:12 AM |
| Cumberland Pharmaceuticals (CPIX) Earns Buy Rating from Analysts at B. Riley
www.americanbankingnews.com - April 17 at 9:19 AM |
 | Cumberland Pharmaceuticals Expands into Oncology Support
finance.yahoo.com - April 9 at 9:55 AM |
| Why Cumberland Pharmaceuticals Inc’s (NASDAQ:CPIX) Ownership Structure Is Important
finance.yahoo.com - March 29 at 4:18 PM |
| Newly Published Data Demonstrates 85% Eradication of Ulcer Causing Bacteria
finance.yahoo.com - March 26 at 10:08 AM |
| Cumberland Pharmaceuticals (CPIX) & The Competition Critical Review
www.americanbankingnews.com - March 24 at 9:46 AM |
| Edited Transcript of CPIX earnings conference call or presentation 6-Mar-18 9:30pm GMT
finance.yahoo.com - March 18 at 9:35 AM |
| Cumberland Pharmaceuticals (CPIX) Announces Earnings Results
www.americanbankingnews.com - March 6 at 7:17 PM |
| Cumberland Pharmaceuticals Reports 25% Revenue Growth For The Full Year 2017
finance.yahoo.com - March 6 at 4:39 PM |
| Cumberland Pharmaceuticals, Inc. (CPIX) Shares Bought by Stonepine Capital Management LLC
www.americanbankingnews.com - March 6 at 2:57 PM |
| Cumberland Pharmaceuticals To Announce Fourth Quarter And Annual 2017 Financial Results
finance.yahoo.com - February 27 at 4:53 PM |
| Cumberland Pharmaceuticals (CPIX) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - February 26 at 3:38 AM |
| Why You Need To Look At This Factor Before Buying Cumberland Pharmaceuticals Inc (NASDAQ:CPIX)
finance.yahoo.com - February 23 at 9:35 AM |
| Is Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) A Financially Sound Company?
finance.yahoo.com - February 15 at 4:26 PM |
| Hospira (HSP) versus Cumberland Pharmaceuticals (CPIX) Head to Head Analysis
www.americanbankingnews.com - January 27 at 5:20 PM |
| Financial Comparison: Hospira (HSP) & Cumberland Pharmaceuticals (CPIX)
www.americanbankingnews.com - January 23 at 8:22 AM |
| Head to Head Review: Hospira (HSP) & Cumberland Pharmaceuticals (CPIX)
www.americanbankingnews.com - January 4 at 3:28 PM |
| The fastest-growing Nashville health care company of 2017 might surprise you
finance.yahoo.com - December 27 at 5:59 PM |
| Is Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) Excessively Paying Its CEO?
finance.yahoo.com - December 25 at 6:42 PM |
| Who Owns Cumberland Pharmaceuticals Inc (NASDAQ:CPIX)?
finance.yahoo.com - December 15 at 5:28 PM |
| Cumberland Pharmaceuticals (CPIX) Downgraded to Sell at ValuEngine
www.americanbankingnews.com - December 4 at 10:26 PM |
| Insider Buying: Cumberland Pharmaceuticals, Inc. (CPIX) Director Acquires 3,300 Shares of Stock
www.americanbankingnews.com - November 24 at 7:52 PM |
| Cumberland Pharmaceuticals Inc (CPIX): How Much Growth Is Left In Healthcare?
finance.yahoo.com - November 24 at 11:03 AM |
| ETFs with exposure to Cumberland Pharmaceuticals, Inc. : November 14, 2017
finance.yahoo.com - November 14 at 5:55 PM |
| Cumberland Pharmaceuticals, Inc. :CPIX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 13, 2017
finance.yahoo.com - November 13 at 9:36 PM |
| Edited Transcript of CPIX earnings conference call or presentation 7-Nov-17 9:30pm GMT
finance.yahoo.com - November 8 at 10:07 PM |
| Cumberland Pharmaceuticals Inc. to Host Earnings Call
finance.yahoo.com - November 7 at 10:55 PM |
| Cumberland Pharmaceutical Reports 27% Revenue Growth In The Third Quarter
finance.yahoo.com - November 7 at 10:55 PM |
| Cumberland reports 3Q loss
finance.yahoo.com - November 7 at 10:55 PM |
| Cumberland Pharmaceuticals Inc. (CPIX) Issues Earnings Results
www.americanbankingnews.com - November 7 at 6:34 PM |
| Cumberland Pharmaceuticals Inc. (CPIX) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - November 1 at 10:48 AM |
| Cumberland Pharmaceuticals to Announce Third Quarter 2017 Financial Results
finance.yahoo.com - October 31 at 6:38 PM |
| Should You Be Holding Cumberland Pharmaceuticals Inc (CPIX) Right Now?
finance.yahoo.com - October 30 at 4:17 PM |
| Cumberland Pharmaceuticals Inc (CPIX): Time For A Financial Health Check
finance.yahoo.com - October 27 at 10:33 PM |
| ETFs with exposure to Cumberland Pharmaceuticals, Inc. : October 25, 2017
finance.yahoo.com - October 25 at 7:04 PM |
| Cumberland Pharmaceuticals Inc. (CPIX) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - October 23 at 10:56 AM |
| ETFs with exposure to Cumberland Pharmaceuticals, Inc. : October 9, 2017
finance.yahoo.com - October 9 at 6:02 PM |
| Cumberland Pharmaceuticals, Inc. :CPIX-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017
finance.yahoo.com - October 6 at 5:41 PM |
| Cumberland Pharmaceuticals Launches Promotion of Totect® in The U.S. for Emergency Oncology Intervention
finance.yahoo.com - September 25 at 12:16 PM |
| What Are The Drivers Of Cumberland Pharmaceuticals Inc’s (CPIX) Risks?
finance.yahoo.com - September 13 at 6:41 PM |
| Edited Transcript of CPIX earnings conference call or presentation 8-Aug-17 8:30pm GMT
finance.yahoo.com - August 12 at 3:55 AM |
| Cumberland reports 2Q loss
finance.yahoo.com - August 8 at 10:15 PM |
| Cumberland Pharmaceuticals Inc. (CPIX) Releases Earnings Results
www.americanbankingnews.com - August 8 at 9:30 PM |
| Cumberland Pharmaceutical Reports Double Digit Revenue Growth For The Fourth Consecutive Quarter
finance.yahoo.com - August 8 at 5:13 PM |
| Cumberland Pharmaceuticals Inc. (CPIX) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - August 3 at 10:40 AM |
| Cumberland Pharmaceuticals To Announce Second Quarter 2017 Financial Results
finance.yahoo.com - August 1 at 6:08 PM |
| Cumberland Pharmaceuticals Begin U.S. Shipments Of Dexrazoxane For Oncology Patient Support
finance.yahoo.com - July 31 at 5:23 PM |
| Cumberland Pharmaceuticals Inc. (CPIX) Set to Announce Earnings on Monday
www.americanbankingnews.com - July 24 at 8:49 AM |
| Financial Contrast: Cumberland Pharmaceuticals (NASDAQ:CPIX) and Merus Labs International (MSLI)
www.americanbankingnews.com - July 17 at 10:27 AM |
| ETFs with exposure to Cumberland Pharmaceuticals, Inc. : July 12, 2017
finance.yahoo.com - July 12 at 6:10 PM |
Cumberland Pharmaceuticals (NASDAQ:CPIX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Cumberland Pharmaceuticals (NASDAQ:CPIX) Income Statement, Balance Sheet and Cash Flow Statement
Cumberland Pharmaceuticals (NASDAQ CPIX) Stock Chart for Monday, April, 23, 2018
Loading chart…
